Ruth Ruddle

8PUBLICATIONS
80CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.

Susana Banerjee, Matthew G Krebs, Alastair Greystoke

|Oct 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

Christina Guo, Adam Sharp, Bora Gurel

|Aug 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang

|Apr 03, 2022
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.

Elizabeth A Coker, Adam Stewart, Bugra Ozer

|Sep 23, 2021
Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma.

Diana M Carvalho, Peter J Richardson, Nagore Olaciregui

|Sep 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.

Javier Pascual, Joline S J Lim, Iain R Macpherson

Pageof 2

Frequent Collaborators

5 joint publications

Karen Swales

5 joint publications

Udai Banerji

3 joint publications

Mona Parmar

3 joint publications

Johann S de Bono